Parkinson’s disease (PD) is a progressive disorder of the central nervous system resulting from a loss of dopamine-producing brain cells that affect movement. It’s characterized by slowness, stiffness, resting tremor, speech changes, impaired balance, and potentially nonmotor symptoms like anxiety, depression, and challenges with thinking and memory. While it’s not considered a fatal disease, it is associated with significant morbidity and disability, and complications from PD can challenge vital activities like eating and sleeping.
Parkinson’s disease has become the fastest growing neurological disorder worldwide, with approximately one million people diagnosed in the U.S. The average age at diagnosis for people with PD is 60; as people live longer, the number of people living with PD is predicted to grow significantly over the coming decades. Beyond age, family history, exposure to some toxins, and being male are potential risk factors.
How frequently someone new is diagnosed with Parkinson’s Disease in the U.S.
The prevalence of Parkinson’s disease in America is set to double by 2040:
Source: National Library of Medicine
There is no cure, but there are more and better ways to treat symptoms, including everything from aerobic exercise to medications and even surgeries. Nevertheless, Parkinson’s disease is a chronic, high-burden disease to live with, with uneven access to movement disorder specialists, treatment continuity, and affordable formulations. Hope and opportunity comes from greater awareness, which helps drive more scientific study and community support.
Source: Parkinson’s Foundation
Source: Parkinson’s Foundation
Source: Frontiers in Neurology
Source: Journal of Parkinson's disease
Source: Frontiers in Neurology
For decades, Amneal has been committed to advancing care for people living with Parkinson’s disease, building a portfolio of treatments designed to meet patients’ evolving needs over time.
CREXONT® (carbidopa/levodopa) represents the latest innovation in that effort—an extended-release, dual-phase capsule engineered to deliver more sustained “Good On” time with fewer doses. For people navigating mobility challenges, slowness, or stiffness, this added duration may translate into greater ease, more independence, and more moments that feel like themselves again.
"The approval of CREXONT is a seminal moment in the treatment paradigm for Parkinson's disease. Amneal is so excited to introduce this meaningful new treatment for Parkinson's patients in the U.S. and soon internationally. We are committed to continuing to advance Parkinson's research and development as a leader in the space."Joe Renda
We hosted a Lunch & Learn for our U.S. employees with Dr. Torres-Yaghi, MD, and Dr. Pagan, MD, two respected Movement Disorder Specialists from MedStar Georgetown University Hospital who shared valuable insights into Parkinson’s disease.
Amneal SPARK program
Learn moreThe information presented in this Accessibility Index is compiled from publicly available sources believed to be reliable at the time of publication. However, Amneal makes no representations or warranties, express or implied, regarding the accuracy, completeness, or timeliness of the data provided. The content is for informational purposes only and does not constitute professional advice or endorsement.
The views and opinions expressed in this index do not necessarily reflect those of Amneal, its affiliates, or its employees. Amneal disclaims any liability for any decisions made or actions taken based on the information contained herein.
This index is intended to support awareness and understanding of medicine accessibility and is not a substitute for professional consultation or regulatory guidance. Users are encouraged to verify information independently and consult appropriate experts before making decisions.
By using this site, you acknowledge and agree to these terms.